Oneview Healthcare PLC (ASX:ONE) Analysts Just Slashed This Year's Estimates

The latest analyst coverage could presage a bad day for Oneview Healthcare PLC (ASX:ONE), with the analysts making across-the-board cuts to their statutory estimates that might leave shareholders a little shell-shocked. Both revenue and earnings per share (EPS) forecasts went under the knife, suggesting the analysts have soured majorly on the business.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Following the downgrade, the most recent consensus for Oneview Healthcare from its twin analysts is for revenues of €13m in 2026 which, if met, would be a solid 12% increase on its sales over the past 12 months. Losses are forecast to hold steady at around €0.012 per share. Yet prior to the latest estimates, the analysts had been forecasting revenues of €15m and losses of €0.01 per share in 2026. Ergo, there's been a clear change in sentiment, with the analysts administering a notable cut to this year's revenue estimates, while at the same time increasing their loss per share forecasts.

See our latest analysis for Oneview Healthcare

The consensus price target fell 27% to €0.19, implicitly signalling that lower earnings per share are a leading indicator for Oneview Healthcare's valuation.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. It's clear from the latest estimates that Oneview Healthcare's rate of growth is expected to accelerate meaningfully, with the forecast 26% annualised revenue growth to the end of 2026 noticeably faster than its historical growth of 6.0% p.a. over the past five years. Other similar companies in the industry (with analyst coverage) are also forecast to grow their revenue at 22% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that Oneview Healthcare is expected to grow at about the same rate as the wider industry.

The Bottom Line

The most important thing to take away is that analysts increased their loss per share estimates for this year. Lamentably, they also downgraded their sales forecasts, but the business is still expected to grow at roughly the same rate as the market itself. After such a stark change in sentiment from analysts, we'd understand if readers now felt a bit wary of Oneview Healthcare.

Even so, the longer term trajectory of the business is much more important for the value creation of shareholders. We have analyst estimates for Oneview Healthcare going out as far as 2028, and you can see them free on our platform here.

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies backed by insiders.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.